First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

Lilit Manukyan2025-01-03T13:44:30+01:0003/01/2025|Categories: Media, News, Uncategorised|

Background
This study assessed dolutegravir pharmacokinetics in HIV-infected infants receiving twice-daily (BID) dolutegravir with rifampicin-based tuberculosis (TB) treatment compared to once-daily (OD) dolutegravir without rifampicin.

Conclusions
Dolutegravir BID with rifampicin provided adequate drug exposure in infants, supporting its use for HIV-TB coinfection management. High rates of viral suppression and minimal safety concerns further validate this treatment approach. Paper_Twice-daily-dosing_Oxford-academics_October-2023.pdf (52 downloads )

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

Share